Nanohale AG (ETR:FYB)

BRIEF

published on 09/27/2024 at 22:01, 1 year 4 months ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 year 4 months ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 year 4 months ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 year 4 months ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval
BRIEF

published on 09/17/2024 at 06:55, 1 year 4 months ago

Formycon to Present FYB202 Biosimilar Data at EADV Congress and UEG Week

Clinical Data Biosimilar Formycon FYB202 Ustekinumab
PRESS RELEASE

published on 09/17/2024 at 06:50, 1 year 4 months ago

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Formycon to present clinical data on ustekinumab biosimilar FYB202 at EADV Congress in Amsterdam and UEG Week in Vienna. Biosimilar for psoriasis and IBD in final approval phase

Clinical Data Biosimilar Formycon Ustekinumab Approval Process
BRIEF

published on 08/19/2024 at 14:16, 1 year 5 months ago

First Berlin Equity Research Maintains Buy Rating for Formycon AG

BUY Rating Biosimilars Formycon Revenue Update H1/24 Results
PRESS RELEASE

published on 08/19/2024 at 14:11, 1 year 5 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG (ISIN: DE000A1EWVY8) with H1/24 results, maintaining BUY rating and EUR 80 target price. Formycon raises FY/24 guidance due to stronger than expected results

First Berlin Equity Research BUY Rating Formycon AG H1/24 Results EUR 80 Target Price
BRIEF

published on 08/13/2024 at 06:55, 1 year 5 months ago

Formycon Reports Robust First Half-Year with Significant Milestones

Financial Results Biosimilars Clinical Milestones Formycon FYB201
PRESS RELEASE

published on 08/13/2024 at 06:50, 1 year 5 months ago

Formycon reports a strong first half-year with multiple milestones achieved
Formycon AG reports successful first half-year with key operational, clinical, and regulatory milestones achieved. Group revenue and EBITDA in line with expectations. Invitation to conference call today

Conference Call Revenue Formycon AG Milestones First Half-Year

Published on 01/30/2026 at 14:00, 3 hours 19 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 8 hours 44 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 9 hours 19 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 15 hours 4 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 17 hours 19 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 17:09, 10 minutes ago

Halfords Group PLC: Total Voting Rights
Published on 01/30/2026 at 16:54, 24 minutes ago

Holding(s) in Company
Published on 01/30/2026 at 16:46, 32 minutes ago

Custodian Property Income REIT plc: Investor Presentation via Investor Meet Company
Published on 01/30/2026 at 16:00, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:59, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

View all EQS

Published on 01/30/2026 at 08:00, 9 hours 19 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 23 hours 19 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 23 hours 34 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 23 hours 34 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 23 hours 39 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News